$287 Million is the total value of Avoro Capital Advisors LLC's 41 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 62.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Buy | MIRATI THERAPEUTICS INC. | $30,047,000 | -24.4% | 1,404,055 | +11.6% | 10.48% | -23.5% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $28,934,000 | -15.2% | 3,424,104 | -2.6% | 10.09% | -14.1% |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $22,869,000 | – | 277,272 | +100.0% | 7.98% | – |
| SRPT | Buy | SAREPTA THERAPEUTICS -INC | $22,546,000 | +16.2% | 1,155,000 | +129.6% | 7.86% | +17.7% |
| GILD | New | GILEAD SCIENCES INC | $16,112,000 | – | 175,400 | +100.0% | 5.62% | – |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $16,030,000 | +123.1% | 405,320 | +219.1% | 5.59% | +125.9% |
| LBIO | Sell | LION BIOTECHNOLOGIES INC | $15,876,000 | -35.5% | 3,125,198 | -2.0% | 5.54% | -34.7% |
| CPXX | New | CELATOR PHARMACEUTICALS INC. | $15,621,000 | – | 1,416,257 | +100.0% | 5.45% | – |
| MDVN | New | MEDIVATION INC | $12,445,000 | – | 270,665 | +100.0% | 4.34% | – |
| BMY | New | BRISTOL MYERS SQUIBB CO. | $11,179,000 | – | 175,000 | +100.0% | 3.90% | – |
| AGEN | Buy | AGENUS - INC | $9,988,000 | +0.0% | 2,400,868 | +9.2% | 3.48% | +1.3% |
| ANAC | New | ANACOR PHARMACEUTICALS INC | $8,910,000 | – | 166,700 | +100.0% | 3.11% | – |
| Buy | NEURODERM LTD. | $7,589,000 | -14.4% | 537,477 | +3.4% | 2.65% | -13.3% | |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $7,144,000 | -39.1% | 854,579 | -32.2% | 2.49% | -38.4% |
| TSRO | New | TESARO INC. | $6,605,000 | – | 150,000 | +100.0% | 2.30% | – |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $6,164,000 | -38.3% | 1,145,779 | -0.1% | 2.15% | -37.5% |
| ONTY | Sell | ONCOTHYREON INC | $5,168,000 | -43.5% | 4,069,072 | -1.2% | 1.80% | -42.8% |
| TLGT | Sell | TELIGENT INC. | $4,533,000 | -62.9% | 925,000 | -32.6% | 1.58% | -62.4% |
| LJPC | Sell | LA JOLLA PHARMACEUTICAL CO. | $4,426,000 | -79.1% | 211,672 | -73.0% | 1.54% | -78.8% |
| FBIO | FORTRESS BIOTECH INC. | $4,147,000 | +11.1% | 1,337,869 | 0.0% | 1.45% | +12.5% | |
| PTX | Sell | PERNIX THERAPEUTICS HOLDINGS | $4,084,000 | -73.1% | 3,889,900 | -24.4% | 1.42% | -72.7% |
| VCYT | Sell | VERACYTE INC | $3,945,000 | -26.1% | 730,514 | -1.5% | 1.38% | -25.2% |
| DERM | Sell | DERMIRA INC | $3,619,000 | -70.5% | 175,000 | -50.7% | 1.26% | -70.2% |
| GBT | New | GLOBAL BLOOD THERAPEEUTICS INC | $3,300,000 | – | 208,086 | +100.0% | 1.15% | – |
| IMMU | New | IMMUNOMEDICS INC | $2,626,000 | – | 1,050,457 | +100.0% | 0.92% | – |
| Sell | TRILLIUM THERAPEUTICS INC | $2,115,000 | -33.9% | 228,697 | -9.9% | 0.74% | -33.0% | |
| SRPT | Buy | SAREPTA THERAPEUTICS -INCcall | $2,006,000 | +220.4% | 307,500 | +550.1% | 0.70% | +224.1% |
| VCEL | Sell | VERICEL CORP. | $1,612,000 | -45.0% | 275,000 | -75.8% | 0.56% | -44.3% |
| NK | Sell | NANTKWEST- INC | $1,602,000 | -81.9% | 194,912 | -67.5% | 0.56% | -81.6% |
| EGLTQ | Sell | EGALET CORPORATION. | $1,601,000 | -66.4% | 233,334 | -46.1% | 0.56% | -66.0% |
| AEGR | Sell | AEGERION PHARMACEUTICALS INC | $1,135,000 | -84.7% | 306,800 | -58.2% | 0.40% | -84.5% |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $1,085,000 | – | 74,800 | +100.0% | 0.38% | – |
| CLLS | Sell | CELLECTIS - ADRsponsored ads | $688,000 | -36.6% | 25,000 | -28.6% | 0.24% | -35.8% |
| New | SPDR SERIES TRUST - S&P BIOTECHput | $670,000 | – | 750,000 | +100.0% | 0.23% | – | |
| CBIO | CATALYST BIOSCIENCES INC. | $120,000 | -46.4% | 71,500 | 0.0% | 0.04% | -45.5% | |
| XON | New | INTREXON CORP.call | $60,000 | – | 200,000 | +100.0% | 0.02% | – |
| New | ISHARES RUSSELL 2000 ETFput | $51,000 | – | 250,000 | +100.0% | 0.02% | – | |
| ALQA | Exit | ALLIQUA BIOMEDICAL INC | $0 | – | -839,100 | -100.0% | -0.62% | – |
| AXDX | Exit | ACCELERATE DIAGNOSTICS, INC. | $0 | – | -112,885 | -100.0% | -0.84% | – |
| TNXP | Exit | TONIX PHARMACEUTICALS HLDG | $0 | – | -340,300 | -100.0% | -0.90% | – |
| INNL | Exit | INNOCOLL AGsponsored adr | $0 | – | -501,722 | -100.0% | -1.43% | – |
| AXGT | Exit | AXOVANT SCIENCES LTD. | $0 | – | -307,070 | -100.0% | -1.91% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.